Galectin Therapeutics Inc.

12/08/2025 | Press release | Distributed by Public on 12/08/2025 07:01

Proxy Results (Form 8-K)

Item 5.07
Submission of Matters to a Vote of Security Holders.

At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also approved a non-binding advisory resolution to approved executive compensation and recommended, by non-binding vote, the frequency with which the Company will conduct stockholder advisory votes on executive compensation. Finally, the stockholders ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2025;

The final results of the voting on each matter of business at the 2025 Annual Meeting are as follows:

Election of Directors


Name
Votes For
Votes Withheld
Broker Non-Votes

Gilbert F. Amelio, Ph.D.
25,335,421
874,903
19,513,532

Benjamin S. Carson, Sr., M.D.
25,916,838
293,486
19,513,532

Kary Eldred
25,886,740
323,584
19,513,532

Kevin D. Freeman
25,827,896
382,428
19,513,532

Joel Lewis
25,688,709
521,615
19,513,532

Gilbert S. Omenn, M.D., Ph.D.
25,810,287
400,037
19,513,532

Marc Rubin, M.D.
25,875,306
335,018
19,513,532

Elissa J. Schwartz, Ph.D.
25,920,970
289,354
19,513,532

Harold H. Shlevin, Ph.D.
25,745,010
465,314
19,513,532

Richard E. Uihlein, Chairman
25,907,034
303,290
19,513,532

Richard A. Zordani
25,906,350
303,974
19,513,532

Vote on a non-binding advisory resolution to approve the compensation paid to Galectin's named executive officers, as disclosed in the proxy statement

Votes For
Votes Against
Votes Abstain
Broker Non-Votes
25,260,489
639,415
310,420
19,513,532

- 2 -
Recommendation, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensation

1 year
2 years
3 years
Abstain
3,616,823
406,162
22,075,944
111,295

In accordance with the voting results for this item, the Company's Board of Directors determined that an advisory vote to approve the compensation of the named executive officers of the Company will be conducted every three years, until the next stockholder advisory vote on the frequency of the advisory vote to approve the compensation of the named executive officers of the Company.

Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2025

Votes For
Votes Against
Votes Abstain
45,458,024
142,268
123,564

- 3 -
Galectin Therapeutics Inc. published this content on December 08, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 08, 2025 at 13:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]